1.

A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium.

2.

A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium.

3.

A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium.

4.

A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium.

5.

A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium.

6.

A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium.

7.

A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium.

8.

A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium.

9.

A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium.

1.

Lessons learned about appendiceal neuroendocrine neoplasms from data analysis of the Belgian Cancer Registry 2010-2015.

2.

Lessons learned about appendiceal neuroendocrine neoplasms from data analysis of the Belgian Cancer Registry 2010-2015.

3.

Lessons learned about appendiceal neuroendocrine neoplasms from data analysis of the Belgian Cancer Registry 2010-2015.

4.

Lessons learned about appendiceal neuroendocrine neoplasms from data analysis of the Belgian Cancer Registry 2010-2015.

5.

Lessons learned about appendiceal neuroendocrine neoplasms from data analysis of the Belgian Cancer Registry 2010-2015.

6.

Lessons learned about appendiceal neuroendocrine neoplasms from data analysis of the Belgian Cancer Registry 2010-2015.

7.

Lessons learned about appendiceal neuroendocrine neoplasms from data analysis of the Belgian Cancer Registry 2010-2015.

8.

Lessons learned about appendiceal neuroendocrine neoplasms from data analysis of the Belgian Cancer Registry 2010-2015.

9.

Lessons learned about appendiceal neuroendocrine neoplasms from data analysis of the Belgian Cancer Registry 2010-2015.

1.

Primary therapy and survival in patients over 70 years old with primary central nervous system lymphoma:a contemporary, nationwide, population-based study in the Netherlands

2.

Primary therapy and survival in patients over 70 years old with primary central nervous system lymphoma:a contemporary, nationwide, population-based study in the Netherlands

3.

Primary therapy and survival in patients over 70 years old with primary central nervous system lymphoma:a contemporary, nationwide, population-based study in the Netherlands

4.

Primary therapy and survival in patients over 70 years old with primary central nervous system lymphoma:a contemporary, nationwide, population-based study in the Netherlands

1.

Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma:a contemporary, nationwide, population-based study in the Netherlands

2.

Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma:a contemporary, nationwide, population-based study in the Netherlands

3.

Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma:a contemporary, nationwide, population-based study in the Netherlands

4.

Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma:a contemporary, nationwide, population-based study in the Netherlands

1.

The incidence of major clinical complications in a Dutch transport IVF programme

2.

The incidence of major clinical complications in a Dutch transport IVF programme

3.

The incidence of major clinical complications in a Dutch transport IVF programme

4.

The incidence of major clinical complications in a Dutch transport IVF programme

5.

The incidence of major clinical complications in a Dutch transport IVF programme

6.

The incidence of major clinical complications in a Dutch transport IVF programme

7.

The incidence of major clinical complications in a Dutch transport IVF programme

8.

The incidence of major clinical complications in a Dutch transport IVF programme

9.

The incidence of major clinical complications in a Dutch transport IVF programme

1.

The association of patient and trauma characteristics with the health-related quality of life in a Dutch trauma population

2.

The association of patient and trauma characteristics with the health-related quality of life in a Dutch trauma population

3.

The association of patient and trauma characteristics with the health-related quality of life in a Dutch trauma population

4.

The association of patient and trauma characteristics with the health-related quality of life in a Dutch trauma population

5.

The association of patient and trauma characteristics with the health-related quality of life in a Dutch trauma population

6.

The association of patient and trauma characteristics with the health-related quality of life in a Dutch trauma population

7.

The association of patient and trauma characteristics with the health-related quality of life in a Dutch trauma population

8.

The association of patient and trauma characteristics with the health-related quality of life in a Dutch trauma population

9.

The association of patient and trauma characteristics with the health-related quality of life in a Dutch trauma population

1.

Selection Criteria for Cochlear Implantation in the United Kingdom and Flanders: Toward a Less Restrictive Standard.

2.

Selection Criteria for Cochlear Implantation in the United Kingdom and Flanders: Toward a Less Restrictive Standard.

3.

Selection Criteria for Cochlear Implantation in the United Kingdom and Flanders: Toward a Less Restrictive Standard.

4.

Selection Criteria for Cochlear Implantation in the United Kingdom and Flanders: Toward a Less Restrictive Standard.

5.

Selection Criteria for Cochlear Implantation in the United Kingdom and Flanders: Toward a Less Restrictive Standard.

6.

Selection Criteria for Cochlear Implantation in the United Kingdom and Flanders: Toward a Less Restrictive Standard.

7.

Selection Criteria for Cochlear Implantation in the United Kingdom and Flanders: Toward a Less Restrictive Standard.

8.

Selection Criteria for Cochlear Implantation in the United Kingdom and Flanders: Toward a Less Restrictive Standard.

9.

Selection Criteria for Cochlear Implantation in the United Kingdom and Flanders: Toward a Less Restrictive Standard.

1.

Stage, treatment and survival of low-grade serous ovarian carcinoma in the Netherlands:A nationwide study

2.

Stage, treatment and survival of low-grade serous ovarian carcinoma in the Netherlands:A nationwide study

3.

Stage, treatment and survival of low-grade serous ovarian carcinoma in the Netherlands:A nationwide study

4.

Stage, treatment and survival of low-grade serous ovarian carcinoma in the Netherlands:A nationwide study

1.

A Nationwide Retrospective Analysis of Out-of-Hospital Pediatric Cardiopulmonary Resuscitation Treated by Helicopter Emergency Medical Service in the Netherlands

2.

A Nationwide Retrospective Analysis of Out-of-Hospital Pediatric Cardiopulmonary Resuscitation Treated by Helicopter Emergency Medical Service in the Netherlands

3.

A Nationwide Retrospective Analysis of Out-of-Hospital Pediatric Cardiopulmonary Resuscitation Treated by Helicopter Emergency Medical Service in the Netherlands

1.

Referral patterns of GIST patients:data from a nationwide study

2.

Referral patterns of GIST patients:data from a nationwide study